3 Firms Build Alfasigma's Nearly $800M Intercept Pharma Buy
Italian pharmaceutical giant Alfasigma on Tuesday agreed to acquire U.S.-based Intercept Pharma, in an all-cash deal guided by three law firms and valued at $19 a share, or nearly $800 million....To view the full article, register now.
Already a subscriber? Click here to view full article